Clinical trial
Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl…
NCT00267514 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00267514 |
|---|---|
| Title | Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients |
| Official title | A Randomized, Cross-over Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer Hydrochloride Tablets Dosed Three Times Per Day in Haemodialysis Patients |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Kidney Disease |
| Intervention type | Drug |
| Interventions | sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®), sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®) |
| Enrollment | 31 |
| Start date | Jan 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Dec 21, 2005 |
| Last update posted | Mar 18, 2015 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: